Page 15 - Flipbook

EVOLVING LANDSCAPE OF FIST LINE SYSTEMIC

TREATMENT IN METASTATIC RCC

ccRCC

Good risk Intermediate risk Poor risk

Standard: Standard: Standard:
Pembrolizumab + axitinib Nivolumab + ipilimumab Nivolumab + ipilimumab

Nivolumab + cabozantinib Pembrolizumab + axitinib Pembrolizumab + axitinib
Pembrolizumb + lenvatinib Nivolumab + cabozantinib Nivolumab + cabozantinib
Avelumab + axitinib Pembrolizumb + lenvatinib Pembrolizumb + lenvatinib
Avelumab + axitinib Avelumab + axitinib
Option: Option: Option:
Sunitinib , Pazopanib, Tivozanib Cabozantinib , Sunitinib ,Pazopanib, Tivozanib Cabozantinib Sunitinib , Pazopanib

Adapted from EAU& ESMO 2021 guidelines